Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Thalassemia Treatment Market

Thalassemia Treatment Market Share

Report ID: GMI9438
Published Date: May 2024
Report Format: PDF

Download Free Sample

Thalassemia Treatment Market Share

The thalassemia treatment industry is characterized by the presence of several established and emerging players that offer a variety of treatments across the globe. The market players compete based on factors such as treatment quality, innovation, regulatory compliance, customer service, and pricing strategies.

Thalassemia Treatment Market Companies

Prominent players operating in the thalassemia treatment industry include:

Bluebird Bio
Bristol-Myers Squibb Company
CHIESI Farmaceutici S.p.A.
Kiadis Pharma
Merck & Co., Inc.
Novartis AG
Pfizer, Inc.
SG Phrma Pvt. Lmt.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Thalassemia treatment industry size was worth USD 2.2 billion in 2023 and is projected to expand at 7.4% CAGR from 2024 to 2032, due to the increasing prevalence of thalassemia, rise in awareness regarding thalassemia treatment, and increasing investments in R&D.

The blood transfusions segment accounted for 41.7% revenue share of the thalassemia treatment industry, owing to the ability of these transfusions to provide essential source of healthy red blood cells, improving oxygen delivery to tissues and organs and enhance overall well-being.

The beta thalassemia disease type segment in the thalassemia treatment industry recorded USD 1.9 billion in revenue in 2023 on account of its high prevalence, particularly in populations with a high frequency of carriers, such as those of Mediterranean, Middle Eastern, South Asian, and Southeast Asian descent.

North America thalassemia treatment industry size was USD 873.8 million in 2023 and is estimated to depict 7% CAGR through 2032, due to the presence of strong healthcare infrastructure, specialized treatment centers, and research institutions dedicated to hematology and genetic disorders.